Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for pain, mood, and recovery after hip replacement
ChiCTR2000031960Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in postoperative pain and major depressive disorder (MDD) (3 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: VAS score, Postoperative analgesic pump dosage and 3 more. Planned start May 2020; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
postoperative painmajor depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2000031960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031960.